JP2022512539A5 - - Google Patents
Info
- Publication number
- JP2022512539A5 JP2022512539A5 JP2021511582A JP2021511582A JP2022512539A5 JP 2022512539 A5 JP2022512539 A5 JP 2022512539A5 JP 2021511582 A JP2021511582 A JP 2021511582A JP 2021511582 A JP2021511582 A JP 2021511582A JP 2022512539 A5 JP2022512539 A5 JP 2022512539A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cancer
- binding
- pharmaceutical composition
- subject
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724592P | 2018-08-29 | 2018-08-29 | |
| US62/724,592 | 2018-08-29 | ||
| US201862734948P | 2018-09-21 | 2018-09-21 | |
| US62/734,948 | 2018-09-21 | ||
| US201962823994P | 2019-03-26 | 2019-03-26 | |
| US62/823,994 | 2019-03-26 | ||
| PCT/US2019/048919 WO2020047325A1 (en) | 2018-08-29 | 2019-08-29 | Combination therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512539A JP2022512539A (ja) | 2022-02-07 |
| JPWO2020047325A5 JPWO2020047325A5 (https=) | 2022-09-06 |
| JP2022512539A5 true JP2022512539A5 (https=) | 2022-09-06 |
Family
ID=69644804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511582A Pending JP2022512539A (ja) | 2018-08-29 | 2019-08-29 | 併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210324041A1 (https=) |
| EP (1) | EP3844177A4 (https=) |
| JP (1) | JP2022512539A (https=) |
| KR (1) | KR20210068432A (https=) |
| CN (1) | CN112912384A (https=) |
| AU (1) | AU2019333173A1 (https=) |
| BR (1) | BR112021003683A2 (https=) |
| CA (1) | CA3109401A1 (https=) |
| CO (1) | CO2021003136A2 (https=) |
| MX (1) | MX2021002286A (https=) |
| WO (1) | WO2020047325A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240141014A1 (en) * | 2021-03-03 | 2024-05-02 | Shattuck Labs, Inc. | Mutant pd-1 extracellular domains |
| WO2022212845A2 (en) * | 2021-04-01 | 2022-10-06 | Shattuck Labs, Inc. | Pd-1- and ox40l-based chimeric proteins |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062401A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| RU2766200C1 (ru) * | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| MX2019009812A (es) * | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
-
2019
- 2019-08-29 JP JP2021511582A patent/JP2022512539A/ja active Pending
- 2019-08-29 BR BR112021003683-0A patent/BR112021003683A2/pt not_active Application Discontinuation
- 2019-08-29 CN CN201980068156.4A patent/CN112912384A/zh active Pending
- 2019-08-29 KR KR1020217009193A patent/KR20210068432A/ko not_active Withdrawn
- 2019-08-29 US US17/265,026 patent/US20210324041A1/en not_active Abandoned
- 2019-08-29 WO PCT/US2019/048919 patent/WO2020047325A1/en not_active Ceased
- 2019-08-29 MX MX2021002286A patent/MX2021002286A/es unknown
- 2019-08-29 AU AU2019333173A patent/AU2019333173A1/en not_active Abandoned
- 2019-08-29 CA CA3109401A patent/CA3109401A1/en active Pending
- 2019-08-29 EP EP19855957.7A patent/EP3844177A4/en not_active Withdrawn
-
2021
- 2021-03-10 CO CONC2021/0003136A patent/CO2021003136A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512541A5 (https=) | ||
| JP2022511286A5 (https=) | ||
| CN110869388B (zh) | 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 | |
| AU2017247880B2 (en) | Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion | |
| JP2024532485A (ja) | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| JP6865585B2 (ja) | 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| JP2020530298A5 (https=) | ||
| JP2016187356A5 (https=) | ||
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP7464525B2 (ja) | 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質 | |
| JP2020506727A5 (https=) | ||
| JP2018501197A5 (https=) | ||
| JPWO2021142002A5 (https=) | ||
| JP2022512539A5 (https=) | ||
| WO2017040660A1 (en) | Combination therapy for treatment of disease | |
| CA3133437A1 (en) | Treatment of cancers using sephb4-hsa fusion proteins | |
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| CA3075717A1 (en) | Combination treatment for cancer | |
| Miao et al. | Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells | |
| JPWO2020047328A5 (https=) | ||
| JP7832689B2 (ja) | Ｐｄ－１ポリペプチド変異体 | |
| JPWO2020047319A5 (https=) | ||
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| JP2021500320A (ja) | 癌の治療のための配合剤 | |
| JP2022503621A5 (https=) |